AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-3. (canceled)

4. (currently amended) ~~Vectors~~ A vector for the transfection of human T lymphocytes with antigens expressed on the surface of B-lymphocytes and not present on human normal T lymphocytes.

5. (currently amended) ~~Vectors~~ The vector according to claim 4, ~~including~~ further comprising the gene coding for the human CD20 antigen.

6. (currently amended) ~~Human~~ A human T ~~lymphocytes~~ lymphocyte transduced with antigens expressed on the surface of B-lymphocytes and not present on human normal T lymphocytes.

7. (currently amended) The T ~~lymphocytes~~ lymphocyte according to claim 6 transduced with human CD20 antigen.

8. (new) A method of controlling graft versus host disease (GvHD) in a patient in need of T lymphocyte transplantation, said method comprising:

a) providing donor's T lymphocytes transduced with antigens expressed on the surface of B lymphocytes and not present in human normal T lymphocytes,

b) administering said T lymphocytes to the patient, and

c) once the GvHD is clinically evident, administering antibodies against said antigens to the patient.

9. (new) The method according to claim 8, wherein said antigen expressed on the surface of B lymphocytes are not present in human normal T lymphocytes as selected from the group consisting of CD20, CD19, CD40, CD22, and CD52.

10. (new) The method according to claim 8, wherein said antigen expressed on the surface of B lymphocytes are not present in human normal T lymphocytes as CD20.

11. (new) The method according to claim 8, wherein said antibody is administered by iv route in a dosage range from approximately 50 to approximately 500 mg/m^2 of body surface, one to three times a day until substantial disappearance of the circulating T lymphocytes.

12. (new) The method according to claim 8,

wherein said antigen expressed on the surface of B lymphocytes are not present in human normal T lymphocytes as

selected from the group consisting of CD20, CD19, CD40, CD22, and CD52; and

wherein the antibody will be administered by iv route in a dosage range from approximately 50 to approximately 500 mg/m^2 of body surface, one to three times a day until the almost complete disappearance of the circulating T lymphocytes.

13. (new) The method according to claim 8, wherein the antigen expressed on the surface of B lymphocytes are not present in human normal T lymphocytes as CD20, and wherein the antibody is administered in a dosage range from approximately 50 to approximately 500 mg/m^2 of body surface.

14. (new) The method according to claim 13, wherein the antibody is administered one to three times a day.

15. (new) The method according to claim 8, wherein said antibody is administered by the iv route.

16. (new) The method according to claim 8, wherein said antibody is administered in a dosage range from approximately 50 to approximately 500 mg/m^2 of body surface.

17. (new) The method according to claim 8, wherein the antibody is administered one to three times a day.

18. (new) The method according to claim 8, wherein said antibody is administered in a dosage range from approximately 50 to approximately 500 mg/m^2 of body surface, and wherein said antibody is administered one to three times a day.